File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0168-8510(00)00140-8
- Scopus: eid_2-s2.0-0034987299
- PMID: 11399347
- WOS: WOS:000168372200003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Cost-effectiveness study on influenza prevention in Hong Kong
Title | Cost-effectiveness study on influenza prevention in Hong Kong |
---|---|
Authors | |
Keywords | Health benefits Illness Influenza |
Issue Date | 2001 |
Publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/healthpol |
Citation | Health Policy, 2001, v. 56 n. 3, p. 215-234 How to Cite? |
Abstract | Introduction: Recent studies confirm that influenza vaccination confers health benefits and reduces direct and indirect costs associated with the illness. However, these studies did not examine the situation in southern China, a hypothetical influenza epicentre for the emergence of pandemic influenza viruses. Methods: Surveillance data were collected in Hong Kong in 1993/94 and used economic model was used to estimate the medical and social costs associated with influenza-like illness (ILI) and to predict the cost-effectiveness of implementing an influenza prevention programme. Findings: The estimated ILI incidence was 110/1000. It was highest in those between 1 and 25 years of age while the rate of hospitalization was highest in the elderly. Influenza occurred throughout the study period, which was a mild influenza year. The model predicted more than 660 000 ILI cases in a non-epidemic year, in which influenza B virus predominated, with an average ILI-associated cost of HK$283/case (US$36) and vaccination-associated costs of HK$74 (US$9.50) per vaccinated individual. Conclusion: The medical, social and monetary costs of ILI in Hong Kong were not observed to be large when compared with those in more developed countries where there is a clearly defined influenza season and recognized disease burden. From the perspective of a susceptible individual, the vaccine was cost-effective but from the perspective of society it was not, even with the most cost-effective strategy of targeting the elderly. However, if the vaccine were effective in controlling newly emerging and highly virulent strains, targeted vaccination programmes might be highly cost-effective. Copyright © 2001 Elsevier Science Ireland Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/151558 |
ISSN | 2023 Impact Factor: 3.6 2023 SCImago Journal Rankings: 1.206 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fitzner, KA | en_US |
dc.contributor.author | Shortridge, KF | en_US |
dc.contributor.author | Mcghee, SM | en_US |
dc.contributor.author | Hedley, AJ | en_US |
dc.date.accessioned | 2012-06-26T06:24:39Z | - |
dc.date.available | 2012-06-26T06:24:39Z | - |
dc.date.issued | 2001 | en_US |
dc.identifier.citation | Health Policy, 2001, v. 56 n. 3, p. 215-234 | en_US |
dc.identifier.issn | 0168-8510 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/151558 | - |
dc.description.abstract | Introduction: Recent studies confirm that influenza vaccination confers health benefits and reduces direct and indirect costs associated with the illness. However, these studies did not examine the situation in southern China, a hypothetical influenza epicentre for the emergence of pandemic influenza viruses. Methods: Surveillance data were collected in Hong Kong in 1993/94 and used economic model was used to estimate the medical and social costs associated with influenza-like illness (ILI) and to predict the cost-effectiveness of implementing an influenza prevention programme. Findings: The estimated ILI incidence was 110/1000. It was highest in those between 1 and 25 years of age while the rate of hospitalization was highest in the elderly. Influenza occurred throughout the study period, which was a mild influenza year. The model predicted more than 660 000 ILI cases in a non-epidemic year, in which influenza B virus predominated, with an average ILI-associated cost of HK$283/case (US$36) and vaccination-associated costs of HK$74 (US$9.50) per vaccinated individual. Conclusion: The medical, social and monetary costs of ILI in Hong Kong were not observed to be large when compared with those in more developed countries where there is a clearly defined influenza season and recognized disease burden. From the perspective of a susceptible individual, the vaccine was cost-effective but from the perspective of society it was not, even with the most cost-effective strategy of targeting the elderly. However, if the vaccine were effective in controlling newly emerging and highly virulent strains, targeted vaccination programmes might be highly cost-effective. Copyright © 2001 Elsevier Science Ireland Ltd. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/healthpol | en_US |
dc.relation.ispartof | Health Policy | en_US |
dc.rights | Health Policy. Copyright © Elsevier Ireland Ltd. | - |
dc.subject | Health benefits | - |
dc.subject | Illness | - |
dc.subject | Influenza | - |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Child, Preschool | en_US |
dc.subject.mesh | Cost Of Illness | en_US |
dc.subject.mesh | Cost-Benefit Analysis | en_US |
dc.subject.mesh | Health Care Costs - Classification - Statistics & Numerical Data | en_US |
dc.subject.mesh | Health Services Research | en_US |
dc.subject.mesh | Hong Kong - Epidemiology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunization Programs - Economics | en_US |
dc.subject.mesh | Infant | en_US |
dc.subject.mesh | Influenza Vaccines - Administration & Dosage - Economics | en_US |
dc.subject.mesh | Influenza, Human - Economics - Epidemiology - Prevention & Control | en_US |
dc.subject.mesh | Population Surveillance | en_US |
dc.title | Cost-effectiveness study on influenza prevention in Hong Kong | en_US |
dc.type | Article | en_US |
dc.identifier.email | Shortridge, KF: microgen@hkucc.hku.hk | en_US |
dc.identifier.email | McGhee, SM: smmcghee@hkucc.hku.hk | en_US |
dc.identifier.email | Hedley, AJ: hrmrajh@hkucc.hku.hk | - |
dc.identifier.authority | McGhee, SM=rp00393 | en_US |
dc.identifier.authority | Hedley, AJ=rp00357 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/S0168-8510(00)00140-8 | en_US |
dc.identifier.pmid | 11399347 | - |
dc.identifier.scopus | eid_2-s2.0-0034987299 | en_US |
dc.identifier.hkuros | 57896 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0034987299&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 56 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 215 | en_US |
dc.identifier.epage | 234 | en_US |
dc.identifier.isi | WOS:000168372200003 | - |
dc.publisher.place | Ireland | en_US |
dc.identifier.scopusauthorid | Fitzner, KA=7006433472 | en_US |
dc.identifier.scopusauthorid | Shortridge, KF=34573590200 | en_US |
dc.identifier.scopusauthorid | McGhee, SM=7003288588 | en_US |
dc.identifier.scopusauthorid | Hedley, AJ=7102584095 | en_US |
dc.identifier.issnl | 0168-8510 | - |